CD274 and non-small cell lung carcinoma: Patients with metastatic NSCLC and high PD-L1 expression level who also have a molecular variant that targets the driver oncogene should receive first-line targeted therapy rather than first-line immunotherapy because the former choice yields higher response rates and is better tolerated (39, 84).